世界のエクソソーム技術市場2021年-2031年：種類別（積載貨物、非貨物）、セルソース別、疾患別、エンドユーザー別

• 英文タイトル：Exosome Technologies Market (Exosome Type: Loaded Cargo and Non-cargo; Cell Source: HEK293, MSCs, Platelets, Erythrocytes, Natural Killer Cells [NKs], and Others; Indication: Therapeutics and Diagnostics; and End User: Healthcare Providers, Pharmaceutical & Biotechnology Companies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

• レポートコード：MRC2106B033 • 出版社/出版日：Transparency Market Research / 2021年4月6日 • レポート形態：英文、PDF、301ページ • 納品方法：Eメール • 産業分類：製薬

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Site Licence	￥1,301,660 (USD8,795)	▷ お問い合わせ
Enterprise Licence	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の本調査レポートは、世界のエクソソーム技術市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（積載貨物、非貨物）分析、セルソース別分析、疾患別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを徹底分析したものです。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のエクソソーム技術市場規模：種類別（積載貨物、非貨物） ・世界のエクソソーム技術市場規模：セルソース別 ・世界のエクソソーム技術市場規模：疾患別 ・世界のエクソソーム技術市場規模：エンドユーザー別 ・世界のエクソソーム技術市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況

Exosome Technologies Market – Scope of the Report

TMR’s report on the global exosome technologies market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global exosome technologies market for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global exosome technologies market during the forecast period.

The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global exosome technologies market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global exosome technologies market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global exosome technologies market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global exosome technologies market.

The report delves into the competitive landscape of the global exosome technologies market. Key players operating in the global exosome technologies market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global exosome technologies market that have been profiled in this report.

Key Questions Answered in Exosome Technologies Market Report

What is the revenue forecast for the global exosome technologies market in terms of revenue for the period 2021–2031?
How would various dynamics such as drivers, restraints, opportunities, and trends affect the market?
What is the market size and estimation for the exosome technologies market across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa?
Which regional market is poised to expand at a significant CAGR during the forecast period?
Which product segment is projected to generate considerable revenue in 2031 and which application segment will register the fastest CAGR during the forecast period?
Research Methodology

A unique methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global exosome technologies market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary research sources referred to by analysts during the production of the global exosome technologies market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the exosome technologies market as primary methods.

These primary research respondents have provided exclusive information during interviews, which serves as a validation from the exosome technologies market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global exosome technologies market with accuracy. The study also uses the top-down approach to assess the revenue of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global exosome technologies market more reliably and accurately.

レポート目次

---

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Exosome Technologies Market
4. Market Overview
4.1. Introduction
4.1.1. Exosome Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Exosome Technologies Market Analysis and Forecast, 2015–2031
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.3. Pipeline Analysis
5.4. Technological Advancement
5.5. Licensing deals (IP portfolio/patent/status of – Codiak, Ciloa SAS, Evox, and ExonanoRNA LLC)
6. Global Exosome Technologies Market Analysis and Forecast, by Exosome Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Exosome Type, 2015–2031
6.3.1. Loaded Cargo
6.3.1.1. Peptide
6.3.1.2. siRNA
6.3.1.3. mRNA
6.3.1.4. miRNA
6.3.1.5. Protein
6.3.1.6. Chemical
6.3.1.7. Others
6.3.2. Non-cargo
6.4. Market Attractiveness Analysis, by Exosome Type
7. Global Exosome Technologies Market Analysis and Forecast, by Cell Source
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Market Value Forecast, by Cell Source, 2015–2031
7.2.1. HEK293
7.2.2. MSCs
7.2.3. Platelets
7.2.4. Erythrocytes
7.2.5. Natural Killer Cells (NKs)
7.2.6. Others
7.3. Market Attractiveness Analysis, by Cell Source
8. Global Exosome Technologies Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Market Value Forecast, by Indication, 2015–2031
8.2.1. Therapeutics
8.2.1.1. Oncology
8.2.1.2. Neurodegenerative Diseases
8.2.1.3. Cardiovascular Diseases
8.2.1.4. Infectious Diseases
8.2.1.5. Cosmetics
8.2.1.6. Others
8.2.2. Diagnostics
8.3. Market Attractiveness Analysis, by Indication
9. Global Exosome Technologies Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.1.1. Key Findings / Developments
9.2. Market Value Forecast, by End-user, 2015–2031
9.2.1. Health Care Providers
9.2.2. Pharmaceutical & Biotechnology Companies
9.2.3. Others
9.3. Market Attractiveness Analysis, by End-user
10. Global Exosome Technologies Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Exosome Technologies Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Exosome Type, 2015–2031
11.2.1. Loaded Cargo
11.2.1.1. Peptide
11.2.1.2. siRNA
11.2.1.3. mRNA
11.2.1.4. miRNA
11.2.1.5. Protein
11.2.1.6. Chemical
11.2.1.7. Others
11.2.2. Non-cargo
11.3. Market Value Forecast, by Cell Source, 2015–2031
11.3.1. HEK293
11.3.2. MSCs
11.3.3. Platelets
11.3.4. Erythrocytes
11.3.5. Natural Killer Cells (NKs)
11.3.6. Others
11.4. Market Value Forecast, by Indication, 2015–2031
11.4.1. Therapeutics
11.4.1.1. Oncology
11.4.1.2. Neurodegenerative Diseases
11.4.1.3. Cardiovascular Diseases
11.4.1.4. Infectious Diseases
11.4.1.5. Cosmetics
11.4.1.6. Others
11.4.2. Diagnostics
11.5. Market Value Forecast, by End-user, 2015–2031
11.5.1. Health Care Providers
11.5.2. Pharmaceutical & Biotechnology Companies
11.5.3. Others
11.6. Market Value Forecast, by Country, 2015–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Exosome Type
11.7.2. By Cell Source
11.7.3. By Indication
11.7.4. By End-user
11.7.5. By Country
12. Europe Exosome Technologies Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Exosome Type, 2015–2031
12.2.1. Loaded Cargo
12.2.1.1. Peptide
12.2.1.2. siRNA
12.2.1.3. mRNA
12.2.1.4. miRNA
12.2.1.5. Protein
12.2.1.6. Chemical
12.2.1.7. Others
12.2.2. Non-cargo
12.3. Market Value Forecast, by Cell Source, 2015–2031
12.3.1. HEK293
12.3.2. MSCs
12.3.3. Platelets
12.3.4. Erythrocytes
12.3.5. Natural Killer Cells (NKs)
12.3.6. Others
12.4. Market Value Forecast, by Indication, 2015–2031
12.4.1. Therapeutics
12.4.1.1. Oncology
12.4.1.2. Neurodegenerative Diseases
12.4.1.3. Cardiovascular Diseases
12.4.1.4. Infectious Diseases
12.4.1.5. Cosmetics
12.4.1.6. Others
12.4.2. Diagnostics
12.5. Market Value Forecast, by End-user, 2015–2031
12.5.1. Health Care Providers
12.5.2. Pharmaceutical & Biotechnology Companies
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2015–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Exosome Type
12.7.2. By Cell Source
12.7.3. By Indication
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Exosome Technologies Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Exosome Type, 2015–2031
13.2.1. Loaded Cargo
13.2.1.1. Peptide
13.2.1.2. siRNA
13.2.1.3. mRNA
13.2.1.4. miRNA
13.2.1.5. Protein
13.2.1.6. Chemical
13.2.1.7. Others
13.2.2. Non-cargo
13.3. Market Value Forecast, by Cell Source, 2015–2031
13.3.1. HEK293
13.3.2. MSCs
13.3.3. Platelets
13.3.4. Erythrocytes
13.3.5. Natural Killer Cells (NKs)
13.3.6. Others
13.4. Market Value Forecast, by Indication, 2015–2031
13.4.1. Therapeutics
13.4.1.1. Oncology
13.4.1.2. Neurodegenerative Diseases
13.4.1.3. Cardiovascular Diseases
13.4.1.4. Infectious Diseases
13.4.1.5. Cosmetics
13.4.1.6. Others
13.4.2. Diagnostics
13.5. Market Value Forecast, by End-user, 2015–2031
13.5.1. Health Care Providers
13.5.2. Pharmaceutical & Biotechnology Companies
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2015–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Exosome Type
13.7.2. By Cell Source
13.7.3. By Indication
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Exosome Technologies Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Exosome Type, 2015–2031
14.2.1. Loaded Cargo
14.2.1.1. Peptide
14.2.1.2. siRNA
14.2.1.3. mRNA
14.2.1.4. miRNA
14.2.1.5. Protein
14.2.1.6. Chemical
14.2.1.7. Others
14.2.2. Non-cargo
14.3. Market Value Forecast, by Cell Source, 2015–2031
14.3.1. HEK293
14.3.2. MSCs
14.3.3. Platelets
14.3.4. Erythrocytes
14.3.5. Natural Killer Cells (NKs)
14.3.6. Others
14.4. Market Value Forecast, by Indication, 2015–2031
14.4.1. Therapeutics
14.4.1.1. Oncology
14.4.1.2. Neurodegenerative Diseases
14.4.1.3. Cardiovascular Diseases
14.4.1.4. Infectious Diseases
14.4.1.5. Cosmetics
14.4.1.6. Others
14.4.2. Diagnostics
14.5. Market Value Forecast, by End-user, 2015–2031
14.5.1. Health Care Providers
14.5.2. Pharmaceutical & Biotechnology Companies
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2015–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Exosome Type
14.7.2. By Cell Source
14.7.3. By Indication
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Exosome Technologies Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Exosome Type, 2015–2031
15.2.1. Loaded Cargo
15.2.1.1. Peptide
15.2.1.2. siRNA
15.2.1.3. mRNA
15.2.1.4. miRNA
15.2.1.5. Protein
15.2.1.6. Chemical
15.2.1.7. Others
15.2.2. Non-cargo
15.3. Market Value Forecast, by Cell Source, 2015–2031
15.3.1. HEK293
15.3.2. MSCs
15.3.3. Platelets
15.3.4. Erythrocytes
15.3.5. Natural Killer Cells (NKs)
15.3.6. Others
15.4. Market Value Forecast, by Indication, 2015–2031
15.4.1. Therapeutics
15.4.1.1. Oncology
15.4.1.2. Neurodegenerative Diseases
15.4.1.3. Cardiovascular Diseases
15.4.1.4. Infectious Diseases
15.4.1.5. Cosmetics
15.4.1.6. Others
15.4.2. Diagnostics
15.5. Market Value Forecast, by End-user, 2015–2031
15.5.1. Health Care Providers
15.5.2. Pharmaceutical & Biotechnology Companies
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2015–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Exosome Type
15.7.2. By Cell Source
15.7.3. By Indication
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis/Ranking, by Company, 2020
16.3. Company Profiles
16.3.1. Aegle Therapeutics
16.3.1.1. Company Overview
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Anjarium Biosciences
16.3.2.1. Company Overview
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. Aruna Biomedical
16.3.3.1. Company Overview
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Carmine Therapeutics
16.3.4.1. Company Overview
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Ciloa SAS
16.3.5.1. Company Overview
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Codiak BioSciences
16.3.6.1. Company Overview
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Creative Biolabs
16.3.7.1. Company Overview
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Danaher Corporation (Beckman Coulter)
16.3.8.1. Company Overview
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
16.3.9. Direct Biologics
16.3.9.1. Company Overview
16.3.9.2. Company Financials
16.3.9.3. Growth Strategies
16.3.9.4. SWOT Analysis
16.3.10. Evercyte
16.3.10.1. Company Overview
16.3.10.2. Company Financials
16.3.10.3. Growth Strategies
16.3.10.4. SWOT Analysis
16.3.11. Evox Therapeutics
16.3.11.1. Company Overview
16.3.11.2. Company Financials
16.3.11.3. Growth Strategies
16.3.11.4. SWOT Analysis
16.3.12. ExoCan Healthcare Technologies Pvt. Ltd.
16.3.12.1. Company Overview
16.3.12.2. Company Financials
16.3.12.3. Growth Strategies
16.3.12.4. SWOT Analysis
16.3.13. ExoCoBio
16.3.13.1. Company Overview
16.3.13.2. Company Financials
16.3.13.3. Growth Strategies
16.3.13.4. SWOT Analysis
16.3.14. ExonanoRNA LLC
16.3.14.1. Company Overview
16.3.14.2. Company Financials
16.3.14.3. Growth Strategies
16.3.14.4. SWOT Analysis
16.3.15. Exopharm
16.3.15.1. Company Overview
16.3.15.2. Company Financials
16.3.15.3. Growth Strategies
16.3.15.4. SWOT Analysis
16.3.16. Exosome Diagnostics, Inc. (BIO-TECHNE CORPORATION)
16.3.16.1. Company Overview
16.3.16.2. Company Financials
16.3.16.3. Growth Strategies
16.3.16.4. SWOT Analysis
16.3.17. Fujifilm
16.3.17.1. Company Overview
16.3.17.2. Company Financials
16.3.17.3. Growth Strategies
16.3.17.4. SWOT Analysis
16.3.18. ILIAS Biologics, Inc.
16.3.18.1. Company Overview
16.3.18.2. Company Financials
16.3.18.3. Growth Strategies
16.3.18.4. SWOT Analysis
16.3.19. Illumina, Inc.
16.3.19.1. Company Overview
16.3.19.2. Company Financials
16.3.19.3. Growth Strategies
16.3.19.4. SWOT Analysis
16.3.20. Invitrix Therapeutics
16.3.20.1. Company Overview
16.3.20.2. Company Financials
16.3.20.3. Growth Strategies
16.3.20.4. SWOT Analysis
16.3.21. XOStem, Inc.
16.3.21.1. Company Overview
16.3.21.2. Company Financials
16.3.21.3. Growth Strategies
16.3.21.4. SWOT Analysis
16.3.22. VivaZome Therapeutics Pty Ltd.
16.3.22.1. Company Overview
16.3.22.2. Company Financials
16.3.22.3. Growth Strategies
16.3.22.4. SWOT Analysis
16.3.23. Thermo Fisher Scientific, Inc.
16.3.23.1. Company Overview
16.3.23.2. Company Financials
16.3.23.3. Growth Strategies
16.3.23.4. SWOT Analysis
16.3.24. Organicell
16.3.24.1. Company Overview
16.3.24.2. Company Financials
16.3.24.3. Growth Strategies
16.3.24.4. SWOT Analysis
16.3.25. OmniSpirant Ltd.
16.3.25.1. Company Overview
16.3.25.2. Company Financials
16.3.25.3. Growth Strategies
16.3.25.4. SWOT Analysis
16.3.26. Novadip Biosciences
16.3.26.1. Company Overview
16.3.26.2. Company Financials
16.3.26.3. Growth Strategies
16.3.26.4. SWOT Analysis
16.3.27. MDimune Inc.
16.3.27.1. Company Overview
16.3.27.2. Company Financials
16.3.27.3. Growth Strategies
16.3.27.4. SWOT Analysis
16.3.28. Lonza
16.3.28.1. Company Overview
16.3.28.2. Company Financials
16.3.28.3. Growth Strategies
16.3.28.4. SWOT Analysis
16.3.29. Kimera Labs
16.3.29.1. Company Overview
16.3.29.2. Company Financials
16.3.29.3. Growth Strategies
16.3.29.4. SWOT Analysis
16.3.30. QIAGEN
16.3.30.1. Company Overview
16.3.30.2. Company Financials
16.3.30.3. Growth Strategies
16.3.30.4. SWOT Analysis
16.3.31. Takara Bio, Inc.
16.3.31.1. Company Overview
16.3.31.2. Company Financials
16.3.31.3. Growth Strategies
16.3.31.4. SWOT Analysis
16.3.32. Tavec Pharma
16.3.32.1. Company Overview
16.3.32.2. Company Financials
16.3.32.3. Growth Strategies
16.3.32.4. SWOT Analysis

---